3D MEDICINES (01244.HK) granted a total of 12.8029 million share options
Gelonghui, April 5 | 3D MEDICINES (01244.HK) announced that on April 5, 2024, the company had offered to grant a total of 12,802,850 share options under the 2023 share option plan, subject to acceptance by the share option grantor.
3D MEDICINES: CLARIFICATION ANNOUNCEMENT REGARDING THE ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
3D Medicines' 2023 Loss Almost Halves as Revenue Jumps 12%
3D Medicines' (HKG:1244) net loss almost halved in 2023 to HK$524.7 million, or HK$2.30 per share, from HK$1.02 billion, or HK$22.52 per share, the previous year, according to an annual report filed T
3D MEDICINES (01244.HK) Announces Annual Results R&D Expenses Increased by 21.3% Forward-looking Layouts for Peptide Oncology Vaccines and mRNA Oncology Vaccines
Gelonghui announced on March 28 | 3D MEDICINES (01244.HK) that in 2023, all of the company's revenue will come from the sale of commercialized Enveda (Envolimab, subcutaneous PD-L1) to pharmacy operators and distributors directly cooperating with the company. For the year ended December 31, 2023, the company's revenue increased 11.9% from RMB 567.4 million in the same period in 2022 to RMB 634.9 million, reflecting the rapid growth in sales since Enveda went public in 2021. Thanks to the diversified advantages of products, ahead of schedule
3D MEDICINES: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 AND PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION OF THE COMPANY
3D MEDICINES (01244.HK) will hold a board meeting on March 28 to approve the full year results
Gelonghui March 18 | 3D MEDICINES (01244.HK) announced that the company will hold a board meeting on March 28, 2024 to adopt the annual results of the company and its subsidiaries for the year ended 31 December 2023 and consider the payment of a final dividend (if any).
3D MEDICINES:董事會會議召開日期
3D MEDICINES (01244.HK) spent HK$58,500 to buy back 10,000 shares on February 14
On February 14, GLONGHUI | 3D MEDICINES (01244.HK) issued an announcement. On February 14, 2024, it cost HK$58,500 to repurchase 10,000 shares at a repurchase price of HK$5.85 per share.
3D MEDICINES [01244] now reported HK$6.55, an increase of 10.08%
As of 09:31, 3D MEDICINES [01244] reported HK$6.55, up HK$0.6 or 10.08% from yesterday's closing price of HK$5.95, with a turnover of HK$916,700. Today's high price was HK$6.55 and the lowest price was HK$6.21. Based on yesterday's closing price, the 10-day average price was HK$5.90, and the 50-day average price was HK$7.24.
3D MEDICINES [01244] now reported HK$6.45, an increase of 10.26%
As of 10:49, 3D MEDICINES [01244] reported HK$6.45, up HK$0.6 or 10.26% from yesterday's closing price. Today's high price was HK$6.45 and the lowest price was HK$5.85. Based on yesterday's closing price, the 10-day average price was HK$5.86, and the 50-day average price was HK$7.31. The current price-earnings ratio was -0.23 times, and the 14-day strong and weak index was reported at 48.00.
Changes in Hong Kong stocks | 3D MEDICINES (01244) rose more than 18% to reach licensing agreements with Corning Jerry and Glenmark for Envolimab
The Zhitong Finance App learned that 3D MEDICINES (01244) rose more than 8% yesterday, and today's intraday increase is more than 18%. As of press release, it rose 14.17% to HK$6.93, with a turnover of HK$22.6018 million. According to the news, Jiangsu Corning Jerry, a wholly-owned subsidiary of Corning Jerry Pharmaceutical-B (09966), and Siludi Pharmaceuticals, a non-wholly-owned subsidiary of 3D Medicines, signed a license agreement with Glenmark, a pharmaceutical company listed in India, and agreed to grant Glenmark kn035 (envolimab injection, trade name: Envy
Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines Announce the Signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies Around the World
Glenmark Specialty S.A. (GSSA), a subsidiary of Glenmark Pharmaceuticals Ltd. (Glenmark), today announced the signing of a license agreement with...
Alphamab Oncology Unit, 3D Medicines Grants Glenmark Unit License to Commercialize Sarcoma Injectable
Alphamab Oncology (HKG:9966) unit Jiangsu Alphamab and 3D Medicines (HKG:1244) granted Glenmark Pharmaceuticals' (NSE:GLENMARK, BOM:532296) Swiss unit, Glenmark Specialty, an exclusive license and a r
Changes in Hong Kong stocks | License agreement reached with Glenmark for KN035 Corning Jerry Pharmaceutical-b (09966) raised more than 8%, 3D MEDICINES (01244) raised more than 7%
Corning Jerry and Siludi Pharmaceuticals announced today that they have reached a licensing agreement with Glenmark for KN035. As of press release, Corning Jerry Pharmaceutical-B (09966) rose 8.15% to HK$5.04; 3D MEDICINES (01244) rose 7.89% to HK$6.02.
3D MEDICINES (01244.HK): License agreement reached with Corning Jerry and GLENMARK for Envolimab
GLONGHUI January 25 | 3D MEDICINES (01244.HK) announced that Siludi Pharmaceutical and Jiangsu Corning Jerry (“Licensee”) and Glenmark (“Licensee”) entered into a license agreement on January 24, 2024. Accordingly, the licensor agreed to grant the licensee Envolimab (also known as “KN035”) (trade name: Envida) (a recombinant humanized single-domain antibody against PD-L1) (a recombinant humanized single-domain antibody against PD-L1) oncology indications developed by the Group in cooperation with Corning Jerry Group a) In India, Asia Pacific (New Zealand)
3D MEDICINES (01244): The 60 million yuan short-term loan granted has been repaid
3D MEDICINES (01244) issued an announcement regarding the company's request to the borrower Qingdao Huiquan Risheng...
SELLAS Life Sciences Seeks Arbitration in Dispute With 3D Medicines
US-based clinical biopharma company SELLAS Life Sciences Group has filed a case against 3D Medicines (HKG:1244) with the Hong Kong International Arbitration Centre, according to a Wednesday disclosure
SELLAS Life Sciences Group And 3D Medicines Engaged In Dispute Regarding, Among Other Things, Trigger & Payment Of Milestone Payments; Regarding Failure To Use Commercially Reasonable Best Efforts To Develop GPS In Licensed Territory Particularly China
SELLAS Life Sciences Group And 3D Medicines Engaged In Dispute Regarding, Among Other Things, Trigger & Payment Of Milestone Payments; Regarding Failure To Use Commercially Reasonable Best Efforts To
3D Medicines Gets US FDA's Nod to Trial Envafolimab; Shares Soar 24%
3D Medicines (HKG:1244) will conduct a clinical trial on its first commercial drug, Envafolimab, in the US after receiving approval from the country's Food and Drug Administration. The phase III study
3D DIAGNOSIS (01244.HK): US FDA Approves Company to Conduct Phase III Clinical Study for Patients with Advanced or Recurrent Endometrial Cancer with Complete Mismatch Repair (pMMR) as First-Line Treatment
Glonghui on October 30丨3D INFECTION (01244.HK) announced that on October 28, 2023, the US Food and Drug Administration (FDA) has approved the company to conduct a phase III multi-country, multi-center, randomized, open-label clinical study on first-line treatment of patients with advanced or recurrent endometrial cancer with complete mismatch repair (PMMR) and complete mismatch repair (PMMR) for patients with advanced or recurrent endometrial cancer. This approval marks a significant step forward for Envida's global development. Envida was approved by the FDA in February 2017 to complete the world's first case
No Data